These target groups include pregnant women, health care workers and patients with underlying chronic diseases, including asthma. A reportve severe asthma may be particularly at risk for infection with the 2009 H1N1 influenza virus. A report published in 2004 suggested that some people who took high doses of glucocorticoids to treat their asthma may receive less protection from influenza vaccines against some strains of influenza. In the early 2009 H1N1 flu outbreak a CDC review of medical records found that people with asthma have a four – fold increased risk of infection compared to the general population at the hospital.Cleveland Clinic, OhioEmory University, AtlantaUniversity of Pittsburgh Asthma InstituteUniversity of Virginia, CharlottesvilleUniversity of Wisconsin: – The study will be conducted at the following locations in MadisonWake Forest University, Winston-Salem, NCWashington University School of Medicine, Louis Detailed information about this study, visit the Clinical Trials..
The study is sponsored by the National Institute of Allergy and Infectious Diseases and the National Heart, and Blood Institute , both part of the NIH. ‘People with severe asthma often high doses of glucocorticoids that can suppress their immune system by a higher risk for infection and possibly serious disease caused by 2009 H1N1 influenza virus,’says NIAID Director Anthony S. MD ‘We need to determine the optimal dose of 2009 H1N1 influenza to be administered safely to this vulnerable population and whether one or two doses are required to elicit an immune response that produce predictive protection.IMPACT: This study provides a deeper insight into the role of immune system of Alzheimer disease and dots on a new treatment approach. Researchers say it may be possible, to a patient test the the immune response of with a blood sample individualized individualize the treatment. The genes into the process, known as MGAT III and Toll-like receptors which involved are also responsible for a number of other major functions within the immune system. The results point also the development of new medications to the disease mixture, Dr John from the amyloid beta – vaccine. The new approach is based on hereditary immune system, rather at birth of antibodies by B-cells, which an later-developed of the active immune systems is established. JOURNAL: The research appears in the 16th July early edition of of Proceedings of National Academy of Sciences..
.’the latest outbreak of H1N1 swine origin flu stresses the incalculability of the of influenza viruses, ‘said Dr. Dan Stinchcomb, Inviragen Chief Executive Officer of. ‘Currently influenza vaccine Manufacturers scrambling concluded seasonal flu vaccine production and attach production of a vaccine to new H1N1 virus. In the future, Inviragen technological could production to allow one single vaccine to both seasonal and pandemic use. ‘.